Metagenomi Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-74.4M | $190.5M |
| FY2023 | — | $-135.6M | $140.6M |
| FY2024 | — | $234.9M | $27.4M |
| FY2025 | — | $158.6M | $41.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-74.4M | $190.5M |
| FY2023 | — | $-135.6M | $140.6M |
| FY2024 | — | $234.9M | $27.4M |
| FY2025 | — | $158.6M | $41.7M |